| Protein / entity | Gene symbol | UniProt ID | Primary function / transport mechanism | Substrates and stoichiometry | Main subcellular localization | Key regulatory / partner molecules | Associated diseases and inheritance | Key biological processes |
|---|---|---|---|---|---|---|---|---|
| H(+)/Cl(-) exchange transporter 7; ClC-7; chloride channel 7 alpha subunit | **CLCN7** | **P51798** | Electrogenic lysosomal **Cl-/H+ antiporter** of the CLC family; each subunit contains an independent transport pathway and the transporter shows slow voltage-dependent activation / strong outward rectification. In acidic compartments, ClC-7 uses the pH gradient to drive luminal chloride accumulation while exporting protons (pqac-00000000, pqac-00000004, pqac-00000011, pqac-00000012) | **2 Cl- exchanged for 1 H+** in opposite directions; in lysosomes/resorption lacuna this is functionally described as uptake of **2 Cl- into the lumen** coupled to **1 H+ efflux** (pqac-00000001, pqac-00000002, pqac-00000004, pqac-00000011) | Predominantly **lysosomal membrane** in most cells; colocalizes with late endosome/lysosome markers; in osteoclasts additionally localizes to the **ruffled border** facing the resorption lacuna, where it supports extracellular acidification for bone resorption (pqac-00000000, pqac-00000005, pqac-00000011) | **OSTM1** is an obligatory beta-subunit required for stability, proper localization, and full function; OSTM1 forms a luminal protective cap over ClC-7. **PI(3,5)P2** directly inhibits ClC-7; disease-causing gain-of-function variants such as **Y715C** and **K285T** reduce this inhibition. Structural/functional determinants include the **gating glutamate E247**, **proton glutamate E314**, ATP/CBS-domain interactions, and a phosphoinositide-binding interface linking transmembrane and cytosolic domains (pqac-00000000, pqac-00000007, pqac-00000011, pqac-00000012) | **Autosomal recessive osteopetrosis (ARO)** due to loss-of-function CLCN7 variants, often with lysosomal storage and possible neurodegeneration; **autosomal dominant osteopetrosis (ADO II / Albers-Schönberg disease)** due to heterozygous variants; **gain-of-function CLCN7 disease / HOD syndrome** with hypopigmentation, organomegaly, delayed myelination and development, and lysosomal storage without classic osteopetrosis; pathogenic CLCN7 dysfunction is also linked to neuronal lysosomal storage disease and retinal/neurologic phenotypes in model systems (pqac-00000000, pqac-00000002, pqac-00000005, pqac-00000010) | **Lysosomal ion homeostasis**; accumulation of luminal chloride; support of lysosomal degradative function and **cathepsin activation**; maintenance of lysosomal membrane integrity; support of **autophagic flux** and cargo degradation; in osteoclasts, support of **bone matrix dissolution/resorption** by helping acidify the resorption lacuna together with V-ATPase (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011) |


*Table: This table summarizes the core molecular properties of human CLCN7/ClC-7, including transport mechanism, localization, regulation, disease associations, and biological roles. It is useful as a compact reference for functional annotation of the human lysosomal Cl-/H+ exchanger.*